VNDA
Vanda Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
FDA Approved
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VNDA
Vanda Pharmaceuticals Inc.
A leading global biopharmaceutical company that develops compounds to treat central nervous system disorders schizophrenia, insomnia and depression
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC 20037
--
Vanda Pharmaceuticals Inc., was incorporated in Delaware in 2002. The company is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. The company strives to advance new approaches to bring important new drugs to market through responsible innovation. The company is committed to using technologies that support sound science, including genetics and genomics, in drug discovery, clinical trials and commercial positioning of products.
Earnings Call
Q3/2025
Estimate EPS-0.45
Actual EPS-0.38
Estimate Revenue58.73M
Actual Revenue56.26M
Vanda Pharmaceuticals' Q3 2025 Earnings Call: Contradictions Emerge on PONVORY Growth and Tradipitant Approval Timelines
Oct 29,2025 10:58
Earnings Decrypt
Earnings Decrypt
Q1/2025
Estimate EPS--
Actual EPS-0.5
Estimate Revenue45.13M
Actual Revenue50.04M
Vanda Pharmaceuticals Q1 2025: Unpacking Key Contradictions in Strategy, Product Launches, and Cash Flow
May 07,2025 08:06
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS--
Actual EPS-0.46
Estimate Revenue54.77M
Actual Revenue52.59M
Vanda Pharmaceuticals' Q2 2025: Navigating Contradictions in Bysanti, PONVORY, and DTC Strategies
Jul 31,2025 04:53
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
VNDA has released its 2025 Q3 earnings. EPS was reported at -0.38, versus the expected -0.45, beating expectations. The chart below visualizes how VNDA has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
VNDA has released its 2025 Q3 earnings report, with revenue of 56.26M, reflecting a YoY change of 18.06%, and net profit of -22.59M, showing a YoY change of -324.23%. The Sankey diagram below clearly presents VNDA's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
